Pharma Industry Finland elects board
This article was originally published in Scrip
Pharma Industry Finland (PIF) has elected a new board. Ilpo Tolonen, managing director of MSD Finland became its new chairman, and Novartis Finland's MD Antti Viitanen and Orion Pharma's director Sari Kailanko were elected Mr Tolonen's first and second deputies respectively. Other board members are Leif Jokinen of H. Lundbeck, Jyrki Liljeroos of Santen, Jaakko Linna of Leiras Finland, Jyrki Lonnfors of AstraZeneca, Liisa Nuuros of Bayer, Harry Rastedt of GlaxoSmithKline, Ari Ronka of Ferring Laakkeet, Markku Santonen of Amgen and Ove Uljas of Pfizer. PIF's managing director, Suvi-Anne Siimes, was appointed the board secretary.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.